Cite
HARVARD Citation
Locatelli, M. et al. (2022). Empagliflozin protects glomerular endothelial cell architecture in experimental diabetes through the VEGF‐A/caveolin‐1/PV‐1 signaling pathway. Journal of pathology. 256 (4), pp. 468-479. [Online].